135065-70-2

Basic information

• Product Name: Morpholine, 2-[(phenylmethoxy)methyl]-, (2R)-
• Synonyms: (-)-2(R)-(phenylmethyloxymethyl)morpholine;.(R)-2-benzyloxymethylmorpholine;.(R)-2-benzyloxymethyl-morpholine
• CAS NO: 135065-70-2
• Molecular Formula: C12H17NO2
• Molecular Weight: 207.272
• Mol File: 135065-70-2.mol

Chemical Properties

• CAS DataBase Reference: Morpholine, 2-[(phenylmethoxy)methyl]-, (2R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Morpholine, 2-[(phenylmethoxy)methyl]-, (2R)-(135065-70-2)
• EPA Substance Registry System: Morpholine, 2-[(phenylmethoxy)methyl]-, (2R)-(135065-70-2)

Safety Data

• Hazardous Substances Data: 135065-70-2(Hazardous Substances Data)

Upstream product

• 926-39-6 sulfuric acid mono-(2-amino-ethyl ester) 
• 14618-80-5 (R)-benzyl glycidol 
• 2930-05-4 Benzyloxymethyl-oxiran 

Downstream Products

• 884512-77-0 (R)-4-(tert-butyloxycarbonyl)morpholine-2-carboxylic acid 
• 952685-69-7 (R)-tert-butyl 2-(3-chlorobenzoyl)morpholine-4-carboxylate 

Relevant articles and documents

Novel hamamelitannin analogues for the treatment of biofilm related MRSA infections–A scaffold hopping approach

Antimicrobial research is increasingly being focused on the problem of resistance and biofilm formation. Hamamelitannin (HAM) was recently identified as an antimicrobial potentiator for conventional antibiotics towards Staphylococcus aureus. This paper de

1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (I) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.

Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket

Structure-based design led to the discovery of a novel class of renin inhibitors in which an unprecedented phenyl ring filling the S1 site is attached to the phenyl ring filling the S3 pocket. Optimization for several parameters including potency in the p

BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF

The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the

BENZAMIDE DERIVATIVES, THEIR PREPARATION AND USES IN MEDICINE THEREOF

The present invention discloses novel benzamide derivatives represented by general formula (I), their preparation, pharmaceutical compositions containing the derivatives and their use as medicament, especially as a 5-HT4 stimulator, wherein the

RENIN INHIBITORS

Disclosed are aspartic protease inhibitors represented by the following structural formula: and pharmaceutically acceptable salts thereof. These compounds are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the t

Renin Inhibitors

Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Described are compounds which bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.

RENIN INHIBITORS

Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR

The present invention provides a compound of a formula (I): wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.